Respiratorius AB (XSAT:RESP) Cyclically Adjusted FCF per Share: kr-1.02 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:RESP Respiratorius AB XSAT:RESP
34 GF Score
Price kr3.00
View Full Analysis

What is Respiratorius AB Cyclically Adjusted FCF per Share?

Respiratorius AB XSAT:RESP -7.69% 34 Cyclically Adjusted FCF per Share is kr-1.02 as of Mar. 2026. GuruFocus rates XSAT:RESP with a GF Score™ of 34/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Respiratorius AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr-0.162. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-1.02 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-14), Respiratorius AB's current stock price is kr3.00. Respiratorius AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-1.02. Respiratorius AB's Cyclically Adjusted Price-to-FCF of today is .


Respiratorius AB  (XSAT:RESP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Respiratorius AB Cyclically Adjusted FCF per Share Related Terms


Respiratorius AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Respiratorius AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Respiratorius AB Cyclically Adjusted FCF per Share Chart

Respiratorius AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -1.98 -1.75 -1.64

Respiratorius AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Apr22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.75 -1.72 -1.67 -1.64 -1.02

XSAT:RESP vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Respiratorius AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Respiratorius AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Respiratorius AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Respiratorius AB's Cyclically Adjusted Price-to-FCF falls into.


XSAT:RESP
34GF Score
Respiratorius AB XSAT:RESP
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Respiratorius AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Respiratorius AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.162/133.5600*133.5600
=-0.162

Current CPI (Mar. 2026) = 133.5600.

Respiratorius AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201603 4.303 100.751 5.704
201606 -0.379 101.019 -0.501
201609 -0.194 101.138 -0.256
201612 -0.297 102.022 -0.389
201703 -0.475 102.022 -0.622
201706 -0.370 102.752 -0.481
201709 -0.012 103.279 -0.016
201712 -11.087 103.793 -14.267
201803 12.909 103.962 16.584
201806 -0.948 104.875 -1.207
201809 -0.315 105.679 -0.398
201812 -1.048 105.912 -1.322
201903 -0.223 105.886 -0.281
201906 -0.442 106.742 -0.553
201909 -1.121 107.214 -1.396
201912 0.170 107.766 0.211
202003 -0.374 106.563 -0.469
202006 -1.592 107.498 -1.978
202009 -0.144 107.635 -0.179
202012 -0.985 108.296 -1.215
202103 -0.459 108.360 -0.566
202106 -0.573 108.928 -0.703
202109 -0.977 110.338 -1.183
202112 0.744 112.486 0.883
202204 0.000 115.534 0.000
202209 0.000 122.296 0.000
202212 0.000 126.365 0.000
202303 -1.829 127.042 -1.923
202306 -0.276 129.407 -0.285
202309 -0.306 130.224 -0.314
202312 -0.216 131.912 -0.219
202403 -0.418 132.205 -0.422
202406 -0.466 132.716 -0.469
202409 -0.319 132.304 -0.322
202412 -0.136 132.987 -0.137
202503 -0.119 132.825 -0.120
202506 -0.221 133.699 -0.221
202509 -0.061 133.480 -0.061
202512 -0.067 133.390 -0.067
202603 -0.162 133.560 -0.162

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-1.02 mean?
Respiratorius AB (XSAT:RESP) has a Cyclically Adjusted FCF per Share of kr-1.02 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Respiratorius AB and its competitors.
Is Respiratorius AB's Cyclically Adjusted FCF per Share too high?
Respiratorius AB's current Cyclically Adjusted FCF per Share is kr-1.02. Overall, Respiratorius AB has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Respiratorius AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Respiratorius AB's Cyclically Adjusted FCF per Share of kr-1.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Respiratorius AB and its competitors. Respiratorius AB's current Cyclically Adjusted FCF per Share is kr-1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Respiratorius AB stock overvalued right now?
Respiratorius AB (XSAT:RESP) has a current Cyclically Adjusted FCF per Share of kr-1.02. The current Cyclically Adjusted FCF per Share is kr-1.02. Respiratorius AB's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Respiratorius AB (XSAT:RESP), the current Cyclically Adjusted FCF per Share is kr-1.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Respiratorius AB Business Description

Address Scheelevagen 2, Medicon Village, Lund, SWE, 223 81
Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000.
34GF Score

Get the complete analysis for XSAT:RESP

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.00
Price